Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin lymphoma, which is difficult to cure and easy to relapse, and the commonly used chemical immunotherapy is not targeted, and often occurs grade 3 or 4 adverse reactions. Ibrutinib can bind to BTK targeting, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells. After oral absorption is rapid, the maximum blood concentration can be reached in 1 to 2 hours, and the adverse reactions belong to grade 1 or 2, which will become a new choice for the treatment of CLL and MCL.